Is Compounded Semaglutide Legal? How the Rules Actually Work in 2026

"Is compounded semaglutide legal?" is the wrong question, and that is why nobody gives you a straight answer. Compounding itself is a lawful, long-established part of American pharmacy. Whether a particular compounded GLP-1, made by a particular facility, for a particular patient, is lawful depends on several conditions at once. Here is the framework, so you can evaluate a seller instead of taking its word.

Start here: legal is not the same as approved

A compounded drug can be lawfully made and dispensed and still not be FDA-approved. Those are two separate ideas that marketing deliberately blurs. The FDA is explicit that compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are sold.

So if a company tells you its product is "legal", it has told you nothing about whether anyone has verified what is in the vial. Ask a different question: who made this, under which licence, and has anyone tested it?

The two kinds of compounder, and why the difference matters to you

Federal law treats compounders in two broad buckets, and the practical consequences for a patient are very different:

• State-licensed pharmacies (traditional compounding). These generally compound for an identified individual patient with a prescription. Critically, the FDA notes that state-licensed pharmacies which are not outsourcing facilities are not required by federal law to report adverse events to the FDA. That is one reason official adverse-event counts for compounded GLP-1s understate reality.
• Outsourcing facilities (registered with the FDA). These operate under tighter federal manufacturing requirements and inspection, and are subject to adverse-event reporting.

Neither route makes the product FDA-approved. But if you are choosing between two sellers at similar prices, knowing which type of facility fills your prescription is real, decision-relevant information. Ask. A provider that will not answer has answered.

The "essentially a copy" limitation

The reason compounded semaglutide and tirzepatide became mass-market products at all is a narrow allowance in federal law. Broadly, compounders are restricted from making products that are essentially copies of a commercially available FDA-approved drug. Exceptions exist — most notably where the approved drug is not available, and where a prescriber determines a particular patient needs a change from the approved product for a documented clinical reason.

This is precisely the space where the GLP-1 compounding market lives, and it is also the space that has been shifting. We are deliberately not going to tell you the current status of any drug shortage listing, because that status changes and a stale claim on a review site is worse than no claim. Check the FDA's own drug shortage database directly if it matters to your decision, and do not accept a seller's characterisation of it.

What you can take away: if a seller's entire legal basis is "there is a shortage", that basis is not permanent, and neither is their business model.

Things that are clearly outside the lines

Some claims are not grey areas at all. From the FDA's own consumer guidance:

• Retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of any FDA-approved drug and have not been found safe and effective for any condition. The FDA says it has warned telehealth companies for marketing unapproved drugs including retatrutide, warned ingredient distributors, and warned outsourcing facilities for repackaging it. If it is on the menu, that tells you what kind of operation you are dealing with.
• Salt forms of semaglutide — semaglutide sodium, semaglutide acetate — are different active ingredients from the one in the approved products, and the FDA says it is not aware of any lawful basis for using them in compounding.
• Fake labels. The FDA reports fraudulent compounded semaglutide and tirzepatide in the US market, sometimes naming compounding pharmacies that do not exist and sometimes naming real pharmacies that did not make the product. It also reports counterfeit Ozempic.
• No prescriber, no prescription. If you can buy without a genuine clinical screening and a prescription from a licensed clinician, you are not in the compounding framework at all.

"Research peptides" and "not for human consumption"

There is a parallel grey market selling GLP-1 peptides labelled for research use, sometimes with "not for human consumption" on the vial. That labelling is not a technicality that protects you; it is the seller placing the entire legal and physical risk on you. There is no prescriber, no pharmacy licence, no cold chain guarantee and no recourse. We do not review these sellers and we will not link to them.

A five-minute due diligence checklist

1. Get the pharmacy name and state that will fill your prescription, in writing, before you pay.
2. Verify that licence on the relevant state board of pharmacy's public lookup. Every state has one.
3. Ask whether it is an FDA-registered outsourcing facility or a state-licensed pharmacy.
4. Ask which form of the active ingredient is used, and confirm it is not a salt form.
5. Open the product page for the exact medication you think you are buying and confirm it has a price and is actually in stock. Several sites advertise FDA-approved brands on the homepage while everything purchasable in the catalogue is compounded — we found this on SkinnyRx, where Wegovy Pill and Foundayo are both listed as unavailable.
6. Confirm there is a named, licensed clinician you can contact after the medication arrives — the FDA lists the absence of this as a warning sign.
7. Ask for the cold-chain plan. If it arrives warm, the FDA's advice is not to use it, so you need to know who eats that cost.

Any legitimate provider can answer all six in one support email. The time it takes them to answer is itself the review.

Where this leaves you

Compounded GLP-1s are not contraband and buying one does not make you a criminal. But "legal" is a much weaker guarantee than most buyers assume, and the strength of the legal basis varies enormously between sellers who charge similar prices. That is the practical case for spending ten minutes on the checklist above rather than optimising for the lowest headline number — see our annualised price comparison, our seven-provider comparison and the FDA's documented concerns.

Sources and limits

Statements attributed to the FDA above are our summary of its consumer guidance page, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, read on August 11, 2026. The description of the compounding framework is a general, simplified summary of federal law and is not legal advice; state law also applies and varies. If you need a determination about a specific product or seller, ask a lawyer or your state board of pharmacy, not a review site.